See more : Augros Cosmetic Packaging SA (AUGR.PA) Income Statement Analysis – Financial Results
Complete financial analysis of GlycoNex Incorporation (4168.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GlycoNex Incorporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Natura &Co Holding S.A. (NTCOY) Income Statement Analysis – Financial Results
- China Calxon Group Co., Ltd. (000918.SZ) Income Statement Analysis – Financial Results
- Lectra SA (LSS.PA) Income Statement Analysis – Financial Results
- Centurion Acquisition Corp. Unit (ALFUU) Income Statement Analysis – Financial Results
- Citizen Watch Co., Ltd. (7762.T) Income Statement Analysis – Financial Results
GlycoNex Incorporation (4168.TWO)
About GlycoNex Incorporation
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under lead optimization stage; GNX202, an antibody drug currently under preclinical stage; and GNX203 and GNX204, antibody drugs currently under target validation stage. It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and SEA (Aflibercept), a vascular endothelial growth factor binding fusion protein, currently under lead optimization stage for the treatment of ophthalmology and oncology. The company was incorporated in 2001 and is based in New Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.54M | 30.09M | 5.48M | 451.00K | 734.00K |
| Cost of Revenue | 1.55M | 16.12M | 2.01M | 326.00K | 585.00K |
| Gross Profit | 995.00K | 13.97M | 3.46M | 125.00K | 149.00K |
| Gross Profit Ratio | 39.14% | 46.43% | 63.21% | 27.72% | 20.30% |
| Research & Development | 210.38M | 197.41M | 145.01M | 156.99M | 218.91M |
| General & Administrative | 45.27M | 50.78M | 48.85M | 52.47M | 48.93M |
| Selling & Marketing | 5.21M | 4.43M | 4.53M | 4.79M | 2.17M |
| SG&A | 50.48M | 55.20M | 53.38M | 57.25M | 51.10M |
| Other Expenses | -259.86M | 18.89M | 19.70M | 52.08M | 0.00 |
| Operating Expenses | 995.00K | 252.61M | 198.39M | 214.24M | 270.01M |
| Cost & Expenses | 262.41M | 268.73M | 200.40M | 214.57M | 270.60M |
| Interest Income | 9.37M | 4.59M | 2.74M | 3.10M | 2.70M |
| Interest Expense | 5.71M | 4.36M | 0.00 | 2.48M | 5.00K |
| Depreciation & Amortization | 31.18M | 39.96M | 40.13M | 46.59M | 54.10M |
| EBITDA | -126.83M | -175.51M | -132.36M | -113.27M | -193.18M |
| EBITDA Ratio | -4,989.26% | -582.35% | -2,417.55% | -24,911.31% | -29,396.05% |
| Operating Income | -259.86M | -215.16M | -172.49M | -158.94M | -269.86M |
| Operating Income Ratio | -10,222.82% | -715.16% | -3,150.56% | -35,240.80% | -36,766.08% |
| Total Other Income/Expenses | 96.15M | -4.67M | 22.44M | 52.71M | 23.19M |
| Income Before Tax | -163.72M | -219.82M | -172.49M | -161.41M | -246.68M |
| Income Before Tax Ratio | -6,440.48% | -730.67% | -3,150.56% | -35,789.58% | -33,607.36% |
| Income Tax Expense | 14.65M | 0.00 | 0.00 | 1.32M | 549.00K |
| Net Income | -178.36M | -219.82M | -172.49M | -162.73M | -247.23M |
| Net Income Ratio | -7,016.60% | -730.67% | -3,150.56% | -36,082.26% | -33,682.15% |
| EPS | -1.65 | -2.21 | -1.78 | -1.82 | -3.26 |
| EPS Diluted | -1.65 | -2.21 | -1.78 | -1.82 | -3.26 |
| Weighted Avg Shares Out | 107.83M | 99.46M | 96.91M | 89.40M | 75.84M |
| Weighted Avg Shares Out (Dil) | 107.83M | 99.46M | 96.91M | 89.40M | 75.84M |
Source: https://incomestatements.info
Category: Stock Reports